These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 16898511)

  • 41. Role of overweight status on stone-forming risk factors in children: a prospective study.
    Sarica K; Eryildirim B; Yencilek F; Kuyumcuoglu U
    Urology; 2009 May; 73(5):1003-7. PubMed ID: 19193407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Citrate and kidney stones].
    Osther PJ
    Ugeskr Laeger; 1993 Nov; 155(47):3835-9. PubMed ID: 8256384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is hypocitraturia associated with phosphaturia--a potential cause of calcium urolithiasis in first-time stone formers.
    Khand FD; Ansari AF; Khand TU; Memon JM
    J Pak Med Assoc; 1994 Aug; 44(8):179-81. PubMed ID: 7996662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prophylaxis of oxalate urolithiasis with alkaline citrates.
    Frang D; Berényi M; Szebeni R
    Ther Hung; 1990; 38(2):64-70. PubMed ID: 2377983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical risk factors for stone formation in healthy school children.
    Akhavan-Sepahi M; Sharifian M; Mohkam M; Vafadar M; Hejazi S
    Acta Med Iran; 2012; 50(12):814-8. PubMed ID: 23456523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Assessment of oxalate concentration in serum and urine of children with renal stones].
    Jadeszko I; Porowski T; Zoch-Zwierz WM; Wasilewska AM; Hackiewicz L
    Wiad Lek; 2005; 58 Suppl 1():20-4. PubMed ID: 16060079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hypocitraturia in children with urolithiasis].
    Kamińska A; Jung A; Piechota W; Kałuza D
    Pol Merkur Lekarski; 2000 Apr; 8(46):181-2. PubMed ID: 10897602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperoxaluria and urolithiasis in young children: an atypical presentation.
    Monico CG; Milliner DS
    J Endourol; 1999 Nov; 13(9):633-6. PubMed ID: 10608514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age-Specific Excretion of Calcium, Oxalate, Citrate, and Glycosaminoglycans and Their Ratios in Healthy Children and Children with Urolithiasis.
    Turudic D; Golubic AT; Lovric M; Bilic M; Milosevic D
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34069381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of crystallization risk formulas in pediatric calcium stone-formers.
    Sikora P; Zajaczkowska M; Hoppe B
    Pediatr Nephrol; 2009 Oct; 24(10):1997-2003. PubMed ID: 19333626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Citrate in daily and fasting urine: results of controls, patients with recurrent idiopathic calcium urolithiasis, and primary hyperparathyroidism.
    Schwille PO; Scholz D; Paulus M; Engelhardt W; Sigel A
    Invest Urol; 1979 May; 16(6):457-62. PubMed ID: 447479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Risk of lithiasis and urolithiasis in children with unspecific inflammatory bowel disease].
    Makosiej R; Czkwianianc E; Niedworok M; Małecka-Panas E
    Pol Merkur Lekarski; 2007 May; 22(131):410-3. PubMed ID: 17679383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
    Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
    Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers.
    Fuselier HA; Moore K; Lindberg J; Husserl FE; Cole FE; Kok DJ; Whitehead D; Galliano DJ; Erwin DT
    Urology; 1998 Dec; 52(6):988-94. PubMed ID: 9836542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pediatric primary urolithiasis: 12-year experience at a Midwestern Children's Hospital.
    Penido MG; Srivastava T; Alon US
    J Urol; 2013 Apr; 189(4):1493-7. PubMed ID: 23201378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of urine composition from split 24-h samples: use of 12-h overnight samples to evaluate risk factors for calcium stones in healthy and stone-forming children.
    Mir C; Rodriguez A; Rodrigo D; Saez-Torres C; Frontera G; Lumbreras J; Espinosa N; Gomez C; Costa-Bauza A; Grases F
    J Pediatr Urol; 2020 Jun; 16(3):371.e1-371.e7. PubMed ID: 32276885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.